Novo Nordisk, the world’s largest insulin manufacturer, has signed an agreement with Saudi Bio to start packaging of Novo Nordisk’s products for the treatment of diabetes, obesity and haemophilia in Saudi Arabia. The agreement was signed in presence of key executives from Novo Nordisk, Saudi Bio, Salehiyah Medical the sole distributor of Novo Nordisk, the Danish Ambassador and top government officials.
The agreement includes packaging of a wide range of products for the treatment of diabetes and haemophilia. The first batch of products is expected by the end of 2019.
“It is a dream coming true when we see insulin production localized in our country. This is in line with the government plans to support technology transfer. We are very thankful for all the support we get from all authorities involved,” explained Dr. Khaled Al Mousa, CEO Saudi Bio Company.
Diabetes is an emergency in slow motion. According to the International Diabetes Federation, in Saudi Arabia alone more than 3.8 million people live with diabetes today and this number is expected to increase by more than 6.5 million by 2045. With this agreement Novo Nordisk will strengthen its presence in the Kingdom and be able to support more people with diabetes to live better lives. The agreement will also help Saudi Arabia realise its Vision 2030 which focuses on localizing production and technology transfer.
“In Novo Nordisk we are committed to help people with diabetes and other chronic diseases live better lives. As part of this, we are localising our manufacturing to bring our products closer to the market,” said Vikrant Shrotriya, Corporate Vice President, Novo Nordisk Saudi Arabia.
Novo Nordisk has been operating with Salehiya in Saudi Arabia since 1991 and currently employs more than 170 employees in the country.
“Being a Saudi myself, it is our pleasure in Salehiya to see what we have been offering to deserving patients being produced in our soil.” Commented Shaikh Sultan Bin Saleh, President of Salehiya Medical.